Utility of Repeating Blood Cultures in Candidemia: Insights From 2 Large Clinical Data Repositories

Clinical Snapshot

Key Findings

• P Value: Not reported in abstract

• Effect Size: 23% of candidemia episodes at Houston Methodist Hospital and 45% in MIMIC-IV were detected by repeat blood cultures following initial negative cultures

• Primary Outcome: Proportion of candidemia episodes detected by repeat blood cultures after an initial negative result

• Nnt Or Sensitivity: Incremental diagnostic sensitivity of repeat blood culture: approximately 23% (HMH) to 45% (MIMIC-IV) additional yield beyond initial culture; overall combined detection rate not explicitly stated. These figures suggest that a single blood culture set misses between 23–45% of ultimately confirmed candidaemia episodes in these populations.

• Confidence Interval: Not reported in abstract

Clinical Application

Repeat blood cultures are a low-cost, widely available, and technically straightforward intervention in hospital settings. The main barriers to implementation are clinician awareness of the incremental yield, standardisation of timing and number of repeat sets, and integration into antimicrobial stewardship and infectious diseases consultation workflows. The findings support a practice already recommended by some expert guidelines but not universally adopted. In Australia, candidaemia management is guided by the Therapeutic Guidelines (Antibiotic) and informed by IDSA and ESCMID guidelines, which recommend serial blood cultures until clearance is confirmed. The TGA-approved antifungal armamentarium includes fluconazole, voriconazole, caspofungin, micafungin, and anidulafungin — all PBS-listed for invasive candidiasis in appropriate indications. Australian tertiary hospitals, particularly those with haematology, solid organ transplant, and ICU services, encounter candidaemia regularly. The RACGP and ACSQHC antimicrobial stewardship frameworks would support formalising repeat blood culture protocols for suspected candidaemia. Local epidemiological data on Candida species distribution (including the emerging threat of Candida auris) should inform institutional protocols. This study's findings, while US-derived, are directionally applicable to Australian tertiary care settings, though local validation through Australian EHR datasets (e.g., via AIHW-linked data or state-based clinical quality registries) would strengthen the evidence base. Hospitalised patients — particularly ICU patients and immunocompromised individuals — with clinical features highly suspicious for candidaemia (unexplained fever, haemodynamic instability, risk factors including prolonged broad-spectrum antibiotics, total parenteral nutrition, central venous catheters, abdominal surgery, or renal replacement therapy) in whom initial blood cultures are negative

Abstract

We evaluated utility of repeating blood culture for candidemia using 2 electronic health record datasets. Among 1386 candidemia episodes, repeated blood culture detected 23% of episodes at Houston Methodist Hospital and 45% in Medical Information Mart for Intensive Care IV after the initial negative cultures. These findings support repeating blood cultures when candidemia is highly suspected.

References

1. 1.Yoshida, H., Adelman, M. W., Ifiora, F., Pérez, M. A., Niravath, M., Yoshimura, H., Jones, S. L., Arias, C. A., & Nigo, M. (2026). Utility of repeating blood cultures in candidemia: Insights from 2 large clinical data repositories. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag216